Kyverna Therapeutics, Inc.KYTXNASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+67.0%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
+67.0%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
4.7x
Strong expansion
Streak
4 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$169.59M+20.7%
2024$140.47M+131.4%
2023$60.70M+66.7%
2022$36.41M+13.8%
2021$32.00M-